NCT02820350已完成不适用
A Multi-Center, Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 19
- 试验地点
- 8
- 主要终点
- Adverse Events
研究概览
简要总结
The SCD (Selective Cytopheretic Device) is an extracorporeal device used as an adjunct to renal replacement therapy (RRT) to improve the outcomes of pediatric patients with acute kidney injury (AKI). Funding Source - FDA OOPD (SCD-PED-01)
详细描述
The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to commercially available Continuous Renal Replacement Therapy (CRRT) devices. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and it is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 22 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A patient, or legal representative, has signed a written informed consent form.
- •Must be receiving medical care in an intensive care unit (e.g., ICU, MICU, SICU, CTICU, Trauma).
- •Age less than 22 years.
- •Females of child bearing potential who are not pregnant (confirmed by a negative serum pregnancy test) and not lactating if recently post-partum.
- •Intent to deliver full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours.
- •Clinical diagnosis of AKI due to etiologies requiring CRRT (see Appendix B). AKI is defined as acute kidney injury with any one of the following:
- •Increase in SCr by ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours or;
- •Increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days or;
- •Urine volume <0.5ml/kg/h for 6 hours
- •At least one non-renal organ failure (defined as receiving mechanical ventilation or at least one vasoactive medication to treat hypotension) OR presence (proven or suspected) of sepsis. (Appendix C).
排除标准
- •Irreversible brain damage based on available historical and clinical information.
- •Presence of any organ transplant at any time.
- •Acute or chronic use of circulatory support device such as LVADs, RVADs, BIVADs, ECMO(a).
- •Presence of preexisting advanced chronic renal failure (i.e., ESRD) requiring CRRT prior to this episode of AKI.
- •AKI occurring in the setting of burns, obstructive uropathy, allergic interstitial nephritis, acute or rapidly progressive glomerulonephritis, vasculitis, hemolytic-uremic syndrome(b), thrombotic thrombocytopenic purpura (TTP), malignant hypertension, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, hepatorenal syndrome, cyclosporine, or tacrolimus nephrotoxicity
- •Received >12hrs of CRRT during this hospital admission or prior to transfer from an outside hospital.
- •Received >1 hemodialysis treatment during this hospital admission or prior to transfer from an outside hospital.
- •Hospitalization >14 days during this hospital admission and or prior to transfer from an outside hospital.
- •Metastatic malignancy which is actively being treated or may be treated by chemotherapy or radiation during the subsequent three-month period after study therapy.
- •Chronic immunosuppression.
- •HIV or AIDS.
- •Severe liver failure(c).
- •Current Do Not Attempt Resuscitation (DNAR), Allow Natural Death (AND), or withdrawal of care status, or anticipated change in status within the next 7 days.
- •Patient is moribund or chronically debilitated for whom full supportive care is not indicated.
- •Patient not expected to survive 28 days because of an irreversible medical condition. (This is not restrictive to AKI, and may include situations such as the presence of irreversible brain damage, untreatable malignancy, inoperable life threatening condition, or any condition to which therapy is regarded as futile by the PI.)
- •Any medical condition that the Investigator thinks may interfere with the study objectives.
- •Physician refusal.
- •Dry weight of <20kg(d).
- •Platelet count <30,000/mm3 at time of screening(e).
- •Concurrent enrollment in another interventional clinical trial. Patients enrolled in clinical trials where only measurements and/or samples are taken (NO TEST DEVICE OR TEST DRUG USED) are allowed to participate.
- •Use of any other Investigational drug or device within the previous 30 days.
- •ECMO was subsequently removed as an exclusion. Two patients in the study received ECMO.
- •Hemolytic uremic syndrome subsequently removed as an exclusion. One patient in the study had HUS.
- •Severe liver failure was change to severe chronic liver failure during the study course.
- •The lower weight limit threshold was decreased to 15 kg after consultation and approval from the US FDA.
- •The thrombocytopenia exclusion removed after no observed occurrences in the first five subjects.
结局指标
主要结局
Adverse Events
时间窗: 60 days post treatment initiation
Adverse events related to device treatment occurring during and 60 days post treatment initiation
次要结局
- All Cause Mortality Through 60 Days Post-randomization.(Day 60)
- Mortality at Day 28(Day 28 following treatment)
- The Effect of SCD Treatment on Renal Replacement Therapy Dependency at Day 60.(60 days)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Safety Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Renal FailureAcute Renal FailureNCT01072682SeaStar Medical35
终止
不适用
A Multi-Center Study of a SCD for Immunomodulatory Dysregulation in Pediatric AKIAcute Kidney InjuryNCT04869787Children's Hospital Medical Center, Cincinnati7
终止
不适用
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney InjuryAcute Kidney InjuryNCT01400893SeaStar Medical134
已完成
不适用
Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 InfectionsARDSCOVIDAKINCT04395911SeaStar Medical22
Unknown
早期 1 期
Feasibility Study of Renal Denervation for the Treatment of Resistant HypertensionUncontrolled HypertensionNCT01865591Sound Interventions, Inc.30